Novel therapeutics in the treatment of systemic lupus erythematosus by Cazacu, Cristina & Cepoi-Bulgac, Daniela
The 8th International Medical Congress for Students and Young Doctors 
 ____________________________________________________________________________________ 
31 
 
DEPARTMENT OF PATHOPHYSIOLOGY AND CLINICAL PATHOPHYSIOLOGY 
 
21. NOVEL THERAPEUTICS IN THE TREATMENT OF SYSTEMIC LUPUS 
ERYTHEMATOSUS  
Author: Cristina Cazacu  
Co-author: Cepoi-Bulgac Daniela  
Scientific adviser: Lutan Vasile, MD, PhD, University Professor, Department of 
pathophysiology and clinical pathophysiology   
Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of 
Moldova.  
 
Background. Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disease 
characterized by loss of immunological tolerance, the system that normally protects self 
components from attack by its own immune system. The current treatment approach includes 
antimalarial drugs, steroidal and nonsteroidal anti-inflammatory agents, and 
immunosuppressive drugs, including cyclophosphamide, azathioprine, mycophenolic acid, and 
methotrexate. Given the large body of evidence implicating abnormalities in the B cell 
compartment in SLE, there has been a particular focus on developing interventions that target 
B cells by multiple mechanisms.T cells play a pivotal role in B-cell  maturation, differentiation, 
antibody production, and class switching. New biological T-cell therapies, including cytokine  
production modulation and T-cell-mediated effects on B cells,  represent a new therapeutic 
strategy for patients with SLE.  
Case report. We report a case of a female patient A, 39 y.o., admitted to Republican Clinical 
Hospital in february 2020. For this admittance she presented, with mild joint pain, oral ulcers 
and mild constitutional signs. She is known with SLE since the age of 26 (presenting with 
photosensitivity, arthritis, oral ulcers). Therapy with prednisolone 0.5mg/kg was started at the 
onset of disease, glucocorticoids being the mainstream treatment for SLE all worldwide, the 
disease was controlled and the patient remained on a stable maintenance dose of 10 mg/day for 
2 years until the pregnancy. During pregnancy the disease was controlled with maintenance 
dose of prednisolone and hydroxychloroquine. Shortly after giving birth the patient developed 
kidney involvement with mild proteinuria up to 1g/24 hours, and hematologic anomalies with 
anemia, leukopenia and thrombocytopenia, diffuse alopecia, arthritis, livedo reticularis. 
Considering the reproductive age of the patient, it was decided to start mycophenolate mofetil 
(and not cyclophosphamide) initially 500mg with a gradual increase to 2 g/24 hours. Presently 
the patient is receiving mycophenolate mofetil 500mg tid, hydroxychloroquine 400mg od, 
methylprednisolone 8mg od. The lab tests upon this admittance showed preserved kidney 
function, only traces of protein in urine, and normal hematology.  
Conclusions. Despite modern emerging biologic therapies of SLE the control of disease and 
preserving kidney functions may be a tricky task. The prompt choice of both efficient and safe 
therapy allowed for the long-term control of disease as well as preserve kidney function.  
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